Clinical Trials
11 trialsNCT04564898 2026-05-20
TriComB
Gruppo Oncologico del Nord-Ovest
Phase 1/2 Active not recruiting
NCT05927857 2026-04-09
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
NCT03223779 2026-03-12
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT07196345 2025-09-29
TAS-102 Plus Radiotherapy in Elderly ESCC
Qianfoshan Hospital
Phase 1/2 Not yet recruiting
NCT04280536 2025-09-23
Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT05508737 2025-07-11
Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer
Yonsei University
Phase 1/2 Active not recruiting
NCT07012954 2025-06-24
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Phase 1/2 Recruiting
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT06379399 2024-04-23
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT06202001 2024-04-02
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed